This webinar has now concluded

Liquid Biopsy Landscape: CtDNA in Lung Cancer Research

ctDNA analysis holds significant promise in lung cancer management, offering opportunities for early detection, personalized treatment selection, and real-time monitoring of treatment response.
Despite its promise, several challenges and limitations remain in the clinical implementation of ctDNA analysis for lung cancer. These include issues related to sensitivity and specificity, detection of low-frequency mutations, standardization of methodologies, and cost-effectiveness. Addressing these challenges will be crucial for further advancing the utility of ctDNA analysis in routine clinical practice.

Liquid Biopsy Landscape Webinar

In this webinar, we delved into the intricacies of analyzing ctDNA and other LBx biomarkers and explored strategies to overcome existing challenges, paving the way for its widespread adoption in clinical settings. Watch the recording now.

Our Experts

Dasha Kaloujskaia

 

House Speaker

Research Analyst

Beacon

Frank Plowden

 

Moderator

Account Manager

Beacon

You May Also Be Interested In…

What is Beacon?

Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more

Menu
Search Icon
Close Icon
Search